Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Axsome Therapeutics (AXSM) Current Leases (2022 - 2025)

Historic Current Leases for Axsome Therapeutics (AXSM) over the last 4 years, with Q3 2025 value amounting to $2.5 million.

  • Axsome Therapeutics' Current Leases rose 5347.26% to $2.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.5 million, marking a year-over-year increase of 5347.26%. This contributed to the annual value of $1.8 million for FY2024, which is 4483.03% up from last year.
  • Axsome Therapeutics' Current Leases amounted to $2.5 million in Q3 2025, which was up 5347.26% from $2.0 million recorded in Q2 2025.
  • In the past 5 years, Axsome Therapeutics' Current Leases registered a high of $2.5 million during Q3 2025, and its lowest value of $108000.0 during Q1 2023.
  • Moreover, its 4-year median value for Current Leases was $1.2 million (2024), whereas its average is $1.1 million.
  • Its Current Leases has fluctuated over the past 5 years, first tumbled by 8883.43% in 2023, then skyrocketed by 96759.26% in 2024.
  • Axsome Therapeutics' Current Leases (Quarter) stood at $425000.0 in 2022, then surged by 198.12% to $1.3 million in 2023, then surged by 44.83% to $1.8 million in 2024, then soared by 36.08% to $2.5 million in 2025.
  • Its Current Leases stands at $2.5 million for Q3 2025, versus $2.0 million for Q2 2025 and $1.8 million for Q1 2025.